Mentari Therapeutics, Inc. is left out of our screens and market counts tonight, which cover US stocks priced at $5 or more and trading at least $1 million a day on average. Its read below still updates after every close.

MTRI· Health Care› Drug Manufacturers - Specialty & Generic

Mentari Therapeutics, Inc.

Stage 2 · Advancing · week 1Setup 6.9 ★★ Good3→2 today

As of Nov 9, 2026, Mentari Therapeutics is in Stage 2, the uptrend phase, now in its first week (since Nov 9, 2026). It closed at $16.00, 13.5% below its 52-week high and above its 200-day average, which is rising. In Health Care, 37.7% of stocks are in Stage 2.

Every stock that changed stage on Nov 9, 2026 →

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. More about the company

$16.00

Close, Nov 9, 2026

+2.83% on the day

$8.5M · Micro cap

Market Neutral — FadingHealth Care 37.7% in Stage 2-5.7 pts / 20dDrug Manufacturers - Specialty & Generic 41.0%-0.8 pts

Pro read

Pro

Our read

A young uptrend, not yet established

Setup score

6.9 ★★ Good

Momentum

Accelerating ⇈

Is MTRI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle TimelineSep 1, 2023 → Nov 9, 2026

S4 28w

S4 23w

S4 21w

S4 43w

Sep 1, 2023Nov 9, 2026

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 28w → S1 2w → S4 23w → S1 4w → S4 3w → S1 3w → S4 5w → S1 3w → S4 21w → S1 7w → S4 43w → S1 7w → S2 7w → S3 11w → S2 1w current

Total tracked: 166 weeks across 15 stage runs.

MTRI among Drug Manufacturers - Specialty & Generic

All 39 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	ETONEton Pharmaceuticals, Inc.	Stage 3 · wk 1	98	+16.6%
2	AMLXAmylyx Pharmaceuticals, Inc.	Stage 3 · wk 1	97	+7.4%
3	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 75	97	+23.8%
4	VTRSViatris Inc.	Stage 2 · wk 58	95	+16.2%
5	XERSXeris Biopharma Holdings, Inc.	Stage 2 · wk 16	95	+51.3%
6	LQDALiquidia Corporation	Stage 4 · wk 2	93	+74.8%
7	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 22	93	+6.9%
8	LNTHLantheus Holdings, Inc.	Stage 3 · wk 10	93	+0.9%

vs 52W High

-13.5%

$6.15 lo$18.50 hi

13.5% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 1

1w13w26w

Week 1, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

31.5%

200 DMA: $12.17 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

7.24x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+17.6%

+9.6%

+157.6%

YTD

+42.9%

-6.2%

Sector

Health Care

↓ Peaking

Stage 2%

37.7%

20d Δ

-5.7pp

1M return

+10.8%

3M return

+14.4%

Sector Stage-2 % · last 20 days

This stock ranks #177 of 188 Stage 2 stocks in Health Care by RS. Lagging sector peers.

Industry

Drug Manufacturers - Specialty & Generic

→ Flat

Stage 2%

41.0%

20d Δ

-0.8pp

1M return

+9.3%

3M return

+12.6%

Industry Stage-2 % · last 20 days

Ranks #17 of 16 Stage 2 stocks in this industry.

Scan Membership

Breakout Watch

Latest: 2021-03-19

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-11-09S23→2

Wk 1 · Vol 7.24x

2026-11-06S3

Wk 11 · Vol 3.85x

2026-11-05S3

Wk 11 · Vol 5.07x

2026-11-04S3

Wk 11 · Vol 1.82x

2026-11-03S3

Wk 10 · Vol 2.73x

2026-11-02S3

Wk 10 · Vol 2.19x

2026-10-30S3

Wk 10 · Vol 0.57x

2026-10-29S3

Wk 10 · Vol 0.58x

2026-10-28S3

Wk 10 · Vol 0.59x

2026-10-27S3

Wk 9 · Vol 1.69x

2026-10-26S3

Wk 9 · Vol 4.68x

2026-10-23S3

Wk 9 · Vol 2.07x

Moving averages & range

50 DMA

$14.00

200 DMA

$12.17

52W High

$18.50

52W Low

$6.15

5D Low

$13.21

Resistance levels (recent highs)

20d High

$17.50

60d High

$17.50

120d High

$18.50

250d High

$18.50

Next resistance

+9.4%

to 20d High

ROE

-156.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 6.6

Against its industry

Drug Manufacturers - Specialty & Generic · 82 companies we cover

Return on equity-156.8%
Higher return on equity than 4%
Profit margin0.0%
Wider margin than 53%
Dividend yield0.00%
Higher yield than 0%

Mentari Therapeutics: quick answers

What stage is Mentari Therapeutics in?

As of Nov 9, 2026, Mentari Therapeutics (MTRI) is in Stage 2, the uptrend phase. It entered Stage 2 on Nov 9, 2026 and is in its first week there. What the four stages mean

Is Mentari Therapeutics in an uptrend?

Yes. Mentari Therapeutics is in a Stage 2 uptrend. It trades 31.5% above its 200-day average, which is rising.

How far is Mentari Therapeutics from its 52-week high?

Mentari Therapeutics closed at $16.00 on Nov 9, 2026, 13.5% below its 52-week high of $18.50. Its 52-week low is $6.15.

How has Mentari Therapeutics performed over the past year?

As of Nov 9, 2026, Mentari Therapeutics is down 6.2% over the past year and up 42.9% so far in 2026.

Which sector and industry is Mentari Therapeutics in?

Mentari Therapeutics is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector. 188 stocks in Health Care are in Stage 2, 37.7% of the sector. See the Stage 2 stocks in Drug Manufacturers - Specialty & Generic

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Visit company website →

All analytics based on EOD data. Data as of Nov 9, 2026. Past data patterns are not indicative of future results. This page is a data analytics tool only.